Skip to main content
HCPCS J3489 · Level II · Part B drug

J3489: zoledronic acid (Reclast), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3489

Billing unit
1 MG
Zoledronic acid 1mg
ASP payment limit
$17.673
October 2026; +425.8% vs July 2026
Practitioner MUE
5
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
1
4 states

TL;DR

HCPCS J3489 is the Level II code for Injection, zoledronic acid, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $17.673 per billing unit, up 425.8% from July 2026. The practitioner MUE allows up to 5 units per date of service (MAI 3), so a full 5-unit day is $88.37 at the current limit. Under OPPS it carries status indicator N. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 25 NDCs to it, sold as Zoledronic Acid, Reclast by Northstar RxLLC, Accord Healthcare Inc, Heritage Pharmaceuticals Inc. 1 Medicare coverage article lists the code across 4 states, including A56907.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3489 at $17.673 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $3.361 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J3489
QuarterPayment limitPerCoinsurance
October 2026$17.6731 MG20%
July 2026$3.3611 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 25 NDCs from 12 labelers to J3489. Report the NDC in the claim's drug segment and bill the number of J3489 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J3489
NDCDrug nameLabelerPackage sizeBilling units / package
16714-0815-01Zoledronic AcidNorthstar RxLLC5 × 14
16729-0242-31Zoledronic AcidAccord Healthcare Inc5 × 14
23155-0170-31Zoledronic AcidHeritage Pharmaceuticals Inc.5 × 14
25021-0801-66Zoledronic AcidSagent Pharmaceuticals5 × 14
25021-0826-67Zoledronic AcidSagent Pharmaceuticals100 × 14
25021-0826-82Zoledronic AcidSagent Pharmaceuticals100 × 14
25021-0830-82Zoledronic AcidSagent Pharmaceuticals100 × 15
25021-0830-87Zoledronic AcidSagent Pharmaceuticals100 × 525
43598-0233-11Zoledronic AcidDr. Reddy's Laboratories Inc.5 × 14
55111-0685-07Zoledronic AcidDr. Reddy's Laboratories Inc.5 × 14
55111-0688-52Zoledronic AcidDr. Reddy's Laboratories Inc.100 × 15
63323-0961-98Zoledronic AcidFreseniUS Kabi USA, LLC5 × 14
63323-0966-00Zoledronic AcidFreseniUS Kabi USA, LLC100 × 15
66758-0155-46ReclastSandoz Inc.100 × 15
67457-0390-54Zoledronic AcidMylan Institutional LLC5 × 14
67457-0619-10Zoledronic AcidMylan Institutional LLC100 × 15
67457-0794-10Zoledronic AcidMylan Institutional LLC100 × 15
68001-0437-25Zoledronic AcidBluePoint Laboratories5 × 14
68001-0610-25Zoledronic AcidBluePoint Laboratories5 × 14
68001-0611-33Zoledronic AcidBluePoint Laboratories100 × 15
70860-0210-51Zoledronic AcidAthenex Pharmaceutical Division, LLC100 × 14
70860-0802-82Zoledronic AcidAthenex Pharmaceutical Division, LLC100 × 15
71288-0806-51Zoledronic AcidMeitheal Pharmaceuticals Inc.100 × 15
72266-0152-01Zoledronic AcidFosun Pharma USA Inc.100 × 15
72603-0198-01Zoledronic AcidNorthstar RxLLC5 × 14

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J3489. For practitioners the limit is 5 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J3489 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services53 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital53 Date of Service Edit: ClinicalPrescribing Information
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J3489 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3489 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3489 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3489 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

1 current Medicare Administrative Contractor article lists J3489 in their HCPCS tables, covering 4 states. Each article carries the covered and non-covered ICD-10 codes that medical-necessity denials (CARC 50) are adjudicated against.

Billing and Coding Articles listing J3489
ArticleTitleContractor(s)StatesRelated LCD
A56907Billing and Coding: Bisphosphonate Drug TherapyWisconsin Physicians Service Insurance CorporationIA KS MO NEL34648, L39721

Diagnoses Medicare contractors cover for J3489

One billing and coding article attaches a covered diagnosis list to J3489: 221 distinct ICD-10-CM codes in all. The 15 below come first by how many of those articles cover them, then in the contractor's own order. The claim line is checked against the list of the contractor that processes it, and a diagnosis outside that list is denied as not medically necessary (CARC 50).

First 15 covered ICD-10-CM codes for J3489
ICD-10-CMDescription (FY2027)Articles covering
C50.011Malignant neoplasm of nipple and areola, right female breast1 of 1
C50.012Malignant neoplasm of nipple and areola, left female breast1 of 1
C50.021Malignant neoplasm of nipple and areola, right male breast1 of 1
C50.022Malignant neoplasm of nipple and areola, left male breast1 of 1
C50.111Malignant neoplasm of central portion of right female breast1 of 1
C50.112Malignant neoplasm of central portion of left female breast1 of 1
C50.121Malignant neoplasm of central portion of right male breast1 of 1
C50.122Malignant neoplasm of central portion of left male breast1 of 1
C50.211Malignant neoplasm of upper-inner quadrant of right female breast1 of 1
C50.212Malignant neoplasm of upper-inner quadrant of left female breast1 of 1
C50.221Malignant neoplasm of upper-inner quadrant of right male breast1 of 1
C50.222Malignant neoplasm of upper-inner quadrant of left male breast1 of 1
C50.311Malignant neoplasm of lower-inner quadrant of right female breast1 of 1
C50.312Malignant neoplasm of lower-inner quadrant of left female breast1 of 1
C50.321Malignant neoplasm of lower-inner quadrant of right male breast1 of 1
206 more codes are in the full lists linked below.

Contractors split an article's diagnoses into numbered groups and say in each group's instructions which procedure codes it supports. Only the groups that apply to J3489 are counted here: a group whose instructions name J3489, together with any unnamed groups directly after it, read as continuations of those instructions. The full list opens on the policy page with every group, the non-covered codes and the instructions.

Covered diagnosis lists that apply to J3489, by article
ArticleContractorGroups that applyCovered codes for J3489Full list
A56907Wisconsin Physicians Service Insurance Corporationgroup 1 applies to J3489221On LCD L34648

Local coverage policies that list J3489

1 active Local Coverage Determination lists J3489 in the policy or in its billing and coding article. Each applies only in its contractor's jurisdiction; check the one for the state where the drug is administered.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3489 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J3489 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J3489 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3489

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3489

What does HCPCS code J3489 describe?

J3489 is defined by CMS as "Injection, zoledronic acid, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3489 a CPT code?

No. J3489 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as zoledronic acid (Reclast); CPT codes are five-character codes maintained by the AMA. On a Part B claim J3489 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3489 in October 2026?

The ASP-based payment limit is $17.673 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $3.361. Commercial payers use their own fee schedules.

How many units of J3489 can be billed per day?

The practitioner Medically Unlikely Edit is 5 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J3489?

The October 2026 ASP crosswalk lists 25 NDCs from 12 labelers: Zoledronic Acid (Northstar RxLLC); Zoledronic Acid (Accord Healthcare Inc); Zoledronic Acid (Heritage Pharmaceuticals Inc.); Zoledronic Acid (Sagent Pharmaceuticals). For example NDC 16714-0815-01 (package size 5) equals 4 billing units of J3489.

Does J3489 have NCCI bundling edits?

No active practitioner PTP pairs list J3489 as a column-1 or column-2 code in the v323r0 release.

Which Medicare coverage articles mention J3489?

1 current Billing and Coding Article in the Medicare Coverage Database lists J3489, covering 4 states: A56907 (Billing and Coding: Bisphosphonate Drug Therapy).

What diagnosis codes support J3489?

One Medicare billing and coding article lists 221 covered ICD-10-CM codes for J3489, for example C50.011 (Malignant neoplasm of nipple and areola, right female breast); C50.012 (Malignant neoplasm of nipple and areola, left female breast); C50.021 (Malignant neoplasm of nipple and areola, right male breast); C50.022 (Malignant neoplasm of nipple and areola, left male breast); C50.111 (Malignant neoplasm of central portion of right female breast). Each contractor's list applies only in its own jurisdiction, so the claim must carry a code from the article of the contractor that processes it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.